Related Experiment Video
Updated: Jan 20, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE
Elisabetta Valoti1, Marina Noris1, Annalisa Perna1
1Aldo e Cele Daccò Clinical Research Center for Rare Diseases, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Ranica, Italy.
Insights
Genetic variants in complement factor H (CFH) are linked to increased risk of kidney and cardiovascular events in type 2 diabetes patients. These CFH variants may reduce the effectiveness of angiotensin-converting enzyme inhibitor (ACEi) therapy.
Area of Science:
- Nephrology
- Cardiology
- Genetics
Background:
- Complement activation plays a role in type 2 diabetes pathogenesis and complications.
- Complement factor H (CFH) genetic variants are linked to organ damage via inefficient complement modulation.
- The impact of specific CFH variants on renal and cardiovascular events in type 2 diabetes, and their interaction with ACEi therapy, remains unclear.
Purpose of the Study:
- To investigate the association of the c.2808G>T (p.Glu936Asp) CFH polymorphism with renal and cardiovascular events in type 2 diabetes patients.
- To determine if this CFH polymorphism influences the response to angiotensin-converting enzyme inhibitor (ACEi) therapy.
- To analyze the risk stratification provided by the p.Glu936Asp polymorphism in the context of microalbuminuria and cardiovascular complications.
Main Methods:
- Analysis of the p.Glu936Asp CFH polymorphism in 1,158 type 2 diabetes patients from the BENEDICT trial.
- Prospective follow-up to assess new onset microalbuminuria and cardiovascular events.
- Multivariable Cox regression analysis to evaluate the association between the polymorphism, ACEi therapy, and clinical outcomes.
Main Results:
- The Asp/Asp genotype of the p.Glu936Asp CFH polymorphism was associated with a significantly increased risk of microalbuminuria (HR 3.25) and cardiovascular events (HR 2.68).
- A significant interaction was observed between the p.Glu936Asp genotype and ACEi therapy regarding microalbuminuria prediction.
- ACEi therapy was not nephroprotective in Asp/Asp homozygotes but was effective in Glu/Asp or Glu/Glu patients. Cardiovascular event risk was higher in ACEi-treated Asp/Asp homozygotes.
Conclusions:
- Type 2 diabetes patients with the Asp/Asp genotype of the p.Glu936Asp CFH polymorphism face a higher risk of microalbuminuria and cardiovascular complications.
- These patients may exhibit a diminished benefit from ACEi therapy.
- Further research is warranted to validate these findings and explore potential therapeutic strategies for this patient subgroup.
Abstract:
Complement activation has been increasingly implicated in the pathogenesis of type 2 diabetes and its chronic complications. It is unknown whether complement factor H (CFH) genetic variants, which have been previously associated with complement-mediated organ damage likely due to inefficient complement modulation, influence the risk of renal and cardiovascular events and response to therapy with angiotensin-converting enzyme inhibitors (ACEi) in type 2 diabetic patients. Here, we have analyzed the c.2808G>T, (p.Glu936Asp) CFH polymorphism, which tags the H3 CFH haplotype associated to low plasma factor H levels and predisposing to atypical hemolytic uremic syndrome, in 1,158 type 2 diabetics prospectively followed in the Bergamo nephrologic complications of type 2 diabetes randomized, controlled clinical trial (BENEDICT) that evaluated the effect of the ACEi trandolapril on new onset microalbuminuria. At multivariable Cox analysis, the p.Glu936Asp polymorphism (Asp/Asp homozygotes, recessive model) was associated with increased risk of microalbuminuria [adjusted hazard ratio (HR) 3.25 (95% CI 1.46-7.24), P = 0.0038] and cardiovascular events [adjusted HR 2.68 (95% CI 1.23-5.87), P = 0.013]. The p.Glu936Asp genotype significantly interacted with ACEi therapy in predicting microalbuminuria. ACEi therapy was not nephroprotective in Asp/Asp homozygotes [adjusted HR 1.54 (0.18-13.07), P = 0.691 vs. non-ACEi-treated Asp/Asp patients], whereas it significantly reduced microalbuminuria events in Glu/Asp or Glu/Glu patients [adjusted HR 0.38 (0.24-0.60), P < 0.0001 vs. non-ACEi-treated Glu/Asp or Glu/Glu patients]. Among ACEi-treated patients, the risk of developing cardiovascular events was higher in Asp/Asp homozygotes than in Glu/Asp or Glu/Glu patients [adjusted HR 3.26 (1.29-8.28), P = 0.013]. Our results indicate that type 2 diabetic patients Asp/Asp homozygotes in the p.Glu936Asp CFH polymorphism are at increased risk of microalbuminuria and cardiovascular complications and may be less likely to benefit from ACEi therapy. Further studies are required to confirm our findings.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Gene Therapy
Types of Impact
The coefficient of restitution is a metric for understanding the dynamics of impacts. It quantifies the ratio of relative velocity...
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Continuous Renal Replacement Therapy

